G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes

Lin LC
University of Glasgow
January 1, 2021
ACS Pharmacol Transl Sci
https://pubmed.ncbi.nlm.nih.gov/34927014

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/34927014

Research summary

Activation of human GPR35 splice variant a (GPR35a) blocks LXR‑induced lipid accumulation in hepatocytes. A humanized knock-in mouse expressing hGPR35a‑HA in place of mouse Gpr35 demonstrated ligand-dependent suppression of hepatic lipid accumulation, overcoming species pharmacology mismatch seen in wild-type mice.

Key outcome of the study

hGPR35a‑HA hepatocytes respond to lodoxamide (EC₅₀ ~17 nM) by blocking and reversing LXR‑induced lipid storage; wild-type mouse GPR35 was unresponsive due to ortholog pharmacological differences

Model

Humanized GPR35a‑HA Knockin mouse (mouse Gpr35 replaced with human splice variant a) — genOway-developed, C57BL/6 background

TARGET:
Gpr35
Synonyms:
CXCR8; DKFZp686A06164; GPR35a

Keywords

Non-alcoholic fatty liver disease (NAFLD); GPCR pharmacology; hepatocyte lipid metabolism; species mismatch; humanization strategy

Technical specifications

Human gene Knockin; replacement of mouse Gpr35; hepatocyte lipid assay; Oil Red O staining; ligand response profiling (lodoxamide, ML‑145)

Related products

Catalogue product

No items found.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe